Novavax is like a specialized vaccine developer aiming to be the next Pfizer or Moderna.

Novavax is like the independent vaccine arm of a major pharmaceutical company like Merck or GSK.

• NVX-CoV2373: A coronavirus vaccine candidate currently in various stages of clinical trials.
• NanoFlu: A nanoparticle seasonal quadrivalent influenza vaccine candidate in Phase 3 clinical trials.
• ResVax: A respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
• RSV F vaccine (for older adults): An RSV vaccine candidate in Phase II clinical trial for individuals 60 years and older.
• RSV F vaccine (for pediatrics): An RSV vaccine candidate in Phase I clinical trial for pediatric use.

Novavax, Inc. (NVAX) sells primarily to other companies and organizations rather than directly to individuals. Based on the provided background information, a major customer company identified through a commercialization agreement is:

• Takeda Pharmaceutical Company Limited (NYSE: TAK)

Takeda Pharmaceutical Company Limited has a collaboration agreement with Novavax for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. This implies Takeda is a significant partner in bringing Novavax's vaccine to market, acting as a major channel or customer for commercialization.

John C. Jacobs – President and Chief Executive Officer

John C. Jacobs joined Novavax as President and CEO in January 2023. He is an industry leader with over 25 years of experience in the pharmaceutical and biotechnology sectors. Prior to Novavax, Mr. Jacobs served as President and CEO of Harmony Biosciences from June 2018 to January 2023, where he successfully led the company through an initial public offering (IPO) and oversaw the FDA review, approval, and commercialization of its first product. He also held various leadership roles at Teva Pharmaceuticals, including Senior Vice President and General Manager of the U.S. Respiratory Business Unit, and positions at Cephalon, Wyeth, and Pfizer.

Jim Kelly – Executive Vice President, Chief Financial Officer and Treasurer

Jim Kelly is the Executive Vice President, Chief Financial Officer, and Treasurer at Novavax, with responsibility for finance, investor relations, and information technology. He joined Novavax with over 25 years of industry experience in both commercial and clinical-stage companies. Previously, Mr. Kelly served as CFO at Supernus Pharmaceuticals and Vanda Pharmaceuticals for ten years, and held various finance leadership roles at MedImmune (now AstraZeneca), Biogen, and Aetna.

Silvia Taylor – Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden

Silvia Taylor serves as Executive Vice President, Chief Corporate Affairs Officer, and Head of Novavax Sweden. Her responsibilities encompass communications, government affairs and policy, corporate reputation and branding, government contracting, and overseeing operations for Novavax's manufacturing and R&D site in Sweden. Ms. Taylor brings over 25 years of experience in commercial operations, corporate affairs, and investor relations within the pharmaceutical and biotechnology sectors. Her background includes key positions at prominent biopharmaceutical firms like Pfizer and MedImmune (now part of AstraZeneca), where she was involved in executive communications, marketing blockbuster and specialty pharmaceuticals, product launches, and capital raising. She has also held senior leadership roles at Autolus Therapeutics plc and Sucampo.

Ruxandra Draghia-Akli, MD, PhD – Executive Vice President, Head of Research & Development

Dr. Ruxandra Draghia-Akli joined Novavax as Executive Vice President and Head of Research & Development in November 2024. She has over 20 years of experience in vaccines and global public health. Prior to Novavax, Dr. Draghia-Akli served as Global Head of Global Public Health R&D at Johnson & Johnson, where she led initiatives in drug discovery and development for diseases such as Dengue, tuberculosis, leprosy, and coronaviruses. She also held the position of Vice President, Global Vaccines at Merck, contributing to the advancement of vaccines against Ebola, pneumococcal disease, and human papillomavirus. Additionally, she worked with the European Commission on research and innovation policy.

Mark Casey – Executive Vice President, Chief Legal Officer and Corporate Secretary

Mark Casey is the Executive Vice President, Chief Legal Officer, and Corporate Secretary at Novavax, a role he assumed in December 2023. He is responsible for legal affairs, including Novavax's patent portfolio, transactional and contractual matters, and public securities filings. Mr. Casey has 25 years of legal experience in the life sciences sector. Before joining Novavax, he served as Chief Legal Officer and Corporate Secretary at Bryn Pharma, LLC, and held similar executive positions at Mallinckrodt Pharmaceuticals, Idera Pharmaceuticals (now Aceragen), and Hologic. At Mallinckrodt, he led strategic turnaround efforts for the Specialty Generics Division. His career also includes roles at Boston Scientific Corp and EMC Corp.

Key Risks to Novavax's Business

Novavax (NVAX) faces significant risks primarily centered around its ability to successfully develop, gain regulatory approval for, and commercialize its vaccine candidates in highly competitive markets, as well as operational challenges related to manufacturing.

1. Clinical Trial Outcomes and Regulatory Approval: Novavax's business success is heavily dependent on the successful completion of clinical trials for its vaccine candidates, including NVX-CoV2373 (COVID-19), NanoFlu (influenza), and ResVax (RSV). The regulatory approval process for vaccines is complex and unpredictable, posing a substantial risk of potential delays or outright failures in obtaining necessary authorizations from health authorities worldwide. Any setbacks in these critical stages could significantly impede the company's ability to commercialize its products and generate revenue.
2. Intense Market Competition and Demand Fluctuations: Novavax operates in vaccine markets, particularly for COVID-19 and influenza, that are characterized by intense competition from established pharmaceutical giants. Even upon receiving regulatory approvals, Novavax faces challenges in securing significant market share and ensuring sufficient uptake of its vaccines. Factors such as pricing, perceived efficacy against evolving viral variants, existing market saturation, and changing public health recommendations can heavily influence demand, as evidenced by the company's struggles with COVID-19 vaccine market share.
3. Manufacturing and Supply Chain Dependence: As a biotechnology company, Novavax relies on third-party manufacturers for critical aspects of its vaccine production. This dependency introduces risks related to potential supply chain disruptions, issues with quality control, and possible delays in large-scale production, which could undermine its capacity to consistently meet market demand for its approved products.

The clear emerging threat for Novavax (NVAX) stems from the **market saturation and early dominance of competing COVID-19 vaccines** already approved, manufactured, and widely distributed by other pharmaceutical companies. While Novavax's NVX-CoV2373 vaccine candidate was still progressing through Phase III clinical trials, other companies secured significant market share and established their products as the primary solutions during the initial rollout of COVID-19 vaccination efforts. This effectively limits the available market opportunity and potential demand for Novavax's vaccine, even upon eventual regulatory approval, mirroring historical scenarios where late-entry products struggle against established alternatives.

Novavax (NVAX) operates in addressable markets for its key vaccine candidates, including COVID-19, seasonal influenza, and respiratory syncytial virus (RSV).

COVID-19 Vaccine (NVX-CoV2373)

• The global COVID-19 vaccine market was valued at approximately USD 13.43 billion in 2024 and is projected to reach USD 29.98 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 9.8% from 2025 to 2033. Another estimate projected the market at USD 25.85 billion by 2030 with a CAGR of 7.4%. Conversely, some reports suggest a contraction, with the market size at USD 13.71 billion in 2025, projected to decline to USD 8.28 billion by 2030, reflecting a -9.10% CAGR.
• Regionally, North America is noted as a dominant force in the COVID-19 vaccine market, claiming 38.2% of the global share in 2024. Asia Pacific has also shown strong market presence, dominating the global COVID-19 vaccine market with over a 58% share in 2021 and is expected to maintain a significant market share with the fastest growth pace.

Influenza Vaccine (NanoFlu)

• The global influenza vaccine market was estimated at USD 8.49 billion in 2024, growing to USD 9.08 billion in 2025, and is anticipated to reach approximately USD 16.73 billion by 2034, with a CAGR of 7.02% between 2025 and 2034. Other projections indicate the global market size was valued at US$ 9.0 billion in 2025 and is expected to reach US$ 18.5 billion by 2036, expanding at a CAGR of 6.8% from 2026 to 2036.
• In the U.S., the influenza vaccine market was valued at USD 4.04 billion in 2023 and is projected to grow at a CAGR of 10.2% during the forecast period. Another source reported the U.S. market at USD 3.65 billion in 2023, with expectations to reach USD 5,770.8 million by 2030 at a CAGR of 6.4% from 2024 to 2030. North America held a significant share of over 53.4% of the global influenza vaccine market in 2024.

Respiratory Syncytial Virus (RSV) Vaccine (ResVax)

• The global RSV vaccine market was estimated at USD 3.51 billion in 2024 and is projected to grow substantially to USD 28.39 billion by 2030, at an impressive CAGR of 42.17% from 2025 to 2030. Another report estimates the global market to grow from USD 5.05 billion in 2025 to around USD 120.86 billion by 2034, at a CAGR of 42.3%. Conversely, other analyses projected the global market to reach USD 1.24 billion by 2030, declining from USD 1.60 billion in 2025 with a CAGR of -4.9% through the forecast period.
• In the U.S., the addressable market for RSV immunizations could potentially exceed USD 19 billion. This figure includes a potential additional USD 5.5 billion if the FDA approves vaccination for the 50-60 age demographic, bringing the total to USD 19.1 billion. Another report valued the U.S. RSV vaccines market at approximately US$ 533.1 million in 2024. The demand for human RSV treatment in the USA, which includes vaccines, is projected to grow from USD 674.6 million in 2025 to USD 1,342.6 million by 2035, at a CAGR of 7.1%.

Novavax (NASDAQ: NVAX) is expected to drive future revenue growth over the next 2-3 years through a strategic shift towards partnerships, leveraging its proprietary Matrix-M adjuvant technology, and advancing its pipeline. Here are the key drivers:

1. Sanofi Partnership for Nuvaxovid and Combination Vaccines: Novavax has transitioned the lead commercial responsibility for its COVID-19 vaccine, Nuvaxovid, to Sanofi for various markets. The company anticipates significant growth in royalties as 2026 marks Sanofi's first full commercial year of selling Nuvaxovid globally. Additionally, future revenue growth is expected from milestone payments related to the Sanofi partnership, including potential payments for a Sanofi Phase III combination study and technology transfer. A key launch from this deal is also expected to be a COVID-flu combination vaccine, utilizing Nuvaxovid, which is projected to be a primary revenue driver starting in late 2026 and 2027 as the market moves towards integrated seasonal vaccinations.
2. Matrix-M Adjuvant Licensing Deals and Expanded Partnerships: Novavax is strategically focusing on out-licensing its Matrix-M adjuvant technology. A significant recent development is the January 2026 license agreement with Pfizer, granting Pfizer non-exclusive rights to use Matrix-M in two infectious disease areas, which could generate up to $500 million in development and sales milestones for Novavax. The company has also signed multiple Material Transfer Agreements (MTAs) with other pharmaceutical companies, indicating increasing interest in its adjuvant technology, and anticipates further new partnership announcements. Novavax's CEO has stated that Matrix-M licensing has the potential to generate "billions of dollars of revenue over time" through milestones and royalties.
3. Advancement of Early-Stage Pipeline: Novavax plans to advance its early-stage pipeline, which includes the development of new adjuvants and exploration of oncology applications. The company has an early-stage C. difficile vaccine candidate and intends to bring these new candidates into clinical trials as early as 2027, diversifying its future revenue streams beyond its current vaccine portfolio.

Share Issuance

• Novavax’s shares outstanding increased by 13.74% in one year as of February 26, 2026.
• In May 2024, Sanofi made a minority equity investment of less than 5% in Novavax as part of a co-exclusive licensing agreement.
• SK bioscience also made an equity investment in Novavax in August 2024.

Inbound Investments

• In May 2024, Novavax entered into a co-exclusive licensing agreement with Sanofi, receiving an upfront payment of $500 million and eligibility for up to $700 million in development, regulatory, and launch milestones for its COVID-19 vaccine and combination COVID-19-Influenza vaccines.
• Novavax signed a non-exclusive license agreement with Pfizer in January 2026 for its Matrix-M adjuvant technology, including an upfront payment of $30 million and potential development and sales milestones of up to $500 million, alongside tiered high-mid-single-digit royalties.
• The company previously received approximately $1.6 billion from Operation Warp Speed in July 2020 to accelerate its COVID-19 vaccine development and manufacturing, and up to $388 million from CEPI for vaccine development and large-scale manufacturing (initial investment March 2020, additional funding May 2020).

Capital Expenditures

• Novavax reported capital expenditures of $57 million in 2021, $93 million in 2022, and $59 million in 2023, followed by -$178 million in 2024.
• Capital expenditures for the last 12 months prior to November 6, 2025, were -$5.42 million. More recently, capital expenditures for the last 12 months (as of February 26, 2026) were -$5.56 million.
• In October 2025, Novavax transferred the lease of its Maryland headquarters to AstraZeneca in a deal worth nearly $60 million, aiming to consolidate facilities, reduce operating costs, and focus on R&D and partnerships.